10-K/A: Autonomix Medical Amends 10-K to Detail Executive Compensation and Corporate Governance

Autonomix Medical, Inc. filed an amendment to its annual report to provide comprehensive details on executive compensation, corporate governance, and related party transactions for the fiscal year ended March 31, 2025.

Summary

• The filing is an Amendment No. 1 to the Annual Report on Form 10-K for the fiscal year ended March 31, 2025, originally filed on May 29, 2025.
• The amendment's sole purpose is to include information required by Items 10 through 14 of Part III, which covers Directors, Executive Officers and Corporate Governance, Executive Compensation, Security Ownership, Certain Relationships and Related Transactions, and Principal Accounting Fees and Services.
• New certifications by the principal executive officer and principal financial officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002, are included.
• The aggregate market value of voting equity held by non-affiliates was $8,113,215 as of the last business day of the most recently completed second fiscal quarter.
• As of July 23, 2025, 5,049,887 shares of common stock were outstanding.
• Executive compensation for fiscal year 2025 included Brad Hauser (CEO) with a total of $1,662,561, Lori Bisson (Vice Chair) with $659,098, Dr. Robert Schwartz (CMO) with $381,111, Landy Toth (CTO) with $313,158, Trent Smith (CFO) with $618,131, and Walter Klemp (Executive Chairman) with $325,658.
• Several executives, including Dr. Robert Schwartz, Landy Toth, and Walter Klemp, took voluntary pay reductions for fiscal year 2025 and effective April 2025 (fiscal year 2026), resulting in their annual salaries being $50,000 on a go-forward basis.
• Bonuses for fiscal year 2025 were awarded based on corporate goals such as securing strategic partnerships, progress on pivotal trials, completion of financings, and completion of clinical proof of concept trials, with Ms. Bisson, Dr. Schwartz, Mr. Smith, and Mr. Hauser achieving 95% of their potential bonuses.
• Audit fees paid to Forvis Mazars, LLP increased from $221,550 in fiscal year 2024 to $505,386 in fiscal year 2025, and tax fees increased from $6,825 to $61,110 over the same period.

Sentiment

Score: 6

Explanation: The filing is largely administrative, providing required disclosures. The detailed corporate governance and compensation policies are positive for transparency. However, the voluntary salary reductions for several key executives could be perceived as a negative signal regarding the company's financial health or outlook, balancing the overall sentiment to moderately positive.

Positives

• The company has a well-defined corporate governance structure with independent Audit, Compensation, and Nominating and Corporate Governance Committees.
• The Audit Committee includes a financial expert, Jonathan Foster, enhancing financial oversight.
• The company has adopted robust policies including an Anti-Hedging Policy, a Code of Ethics, an Insider Trading Policy, and a Dodd-Frank Restatement Recoupment Policy, promoting integrity and accountability.
• Executive compensation is tied to corporate goals, including progress on pivotal trials and strategic partnerships, aligning management incentives with company performance.
• The company's compensation policies are reviewed for risks and are not believed to have a material adverse effect on the business.

Negatives

• Several key executives, including the Chief Medical Officer, Chief Technology Officer, and Executive Chairman, voluntarily reduced their salaries significantly for fiscal years 2025 and 2026, which could indicate cost-cutting measures or financial constraints.
• Lori Bisson's annual base salary was decreased from $375,000 to $150,000 upon transitioning from Chief Executive Officer to Vice Chair in June 2024.

Risks

• The filing does not explicitly detail new or updated operational or financial risks beyond those typically associated with executive compensation and corporate governance disclosures. It primarily focuses on the administrative update of Part III information.

Future Outlook

The filing provides forward-looking statements regarding executive compensation targets for fiscal year 2026, indicating continued focus on strategic partnerships, pivotal trial progress, financings, catheter design lock, and completion of the second phase of the clinical proof of concept trial as key performance indicators for bonuses. However, no specific financial guidance or broader strategic outlook is provided in this amendment.

Management Comments

• Dr. Schwartz agreed to provide services on a part-time basis of 25% of his working time.
• Mr. Toth agreed to provide services on a part-time basis of 25% of his working time.
• The Compensation Committee is not required to calculate bonuses in a specific manner and retains discretion in the amounts it awards and the factors it takes into consideration.
• The Compensation Committee reviews compensation annually for all employees, including executives, considering compensation for comparable positions, individual performance, motivation, and long-term commitment.
• The company does not believe that any risks relating to its compensation policies and practices for employees are reasonably likely to have a material adverse effect on its business.

Industry Context

This amendment primarily focuses on internal corporate governance and executive compensation, which are standard disclosures for publicly traded companies. It does not provide specific insights into broader medical device industry trends or competitive positioning, but the mention of 'pivotal trial' and 'clinical proof of concept trial' suggests ongoing R&D in the medical device sector.

Comparison to Industry Standards

• The executive compensation structure, including base salary, non-equity incentives, and stock options, aligns with common practices in the medical device and biotechnology industries for attracting and retaining talent.
• The establishment of independent audit, compensation, and nominating/corporate governance committees, along with policies like anti-hedging and recoupment, demonstrates adherence to best practices in corporate governance for Nasdaq-listed companies.
• The increase in audit fees from FY2024 to FY2025 is significant, potentially reflecting increased audit complexity or scope, which should be monitored against industry averages for companies of similar size and stage.

Management Changes

Corporate Governance

Related Party Transactions

• In December 2021, the company granted a license to its technology for use in cardiology to a company affiliated with certain early investors.
• In July 2023, this license agreement was terminated in exchange for a warrant to purchase 80,000 shares of common stock at an exercise price of $0.02 per share upon the closing of the IPO.
• Director David Robins holds a 19.5% interest in the company that received this warrant (Impulse Medical, Inc.).
• Subsequent to September 30, 2023, members of the company's management, Board of Directors, and an immediate family member of management collectively purchased $500,000 in principal amount of convertible notes in a private placement.

Stakeholder Impact

• Shareholders: The detailed disclosures on executive compensation, corporate governance, and related party transactions provide increased transparency, which can aid in investment decisions. The voluntary pay reductions by some executives could be viewed negatively by some shareholders, while the robust governance policies are positive.
• Employees: The compensation policies and equity incentive plans are designed to motivate and retain key employees, aligning their interests with company performance.
• Management: Executive compensation is directly tied to corporate goals, providing clear incentives for performance. Changes in roles and compensation for key executives like Brad Hauser and Lori Bisson directly impact their individual financial outlook and responsibilities.

Next Steps

• The Compensation Committee will continue to determine annual option grants for executives based on established criteria.
• Bonuses for fiscal year 2026 will be awarded based on achievement of specified corporate goals, including securing strategic partnerships, progress on pivotal trials, completion of financings, design lock for catheter, and completion of the second phase of the clinical proof of concept trial.

Key Dates

Recommendation

This filing is an administrative amendment to an annual report, primarily providing detailed disclosures on corporate governance, executive compensation, and related party transactions. It does not contain new financial performance data, operational updates, or forward-looking guidance that would significantly alter the company's valuation or investment thesis. While the voluntary pay reductions by some executives could be a minor concern, the overall content is informational rather than indicative of a strong 'buy' or 'sell' signal. Therefore, a 'hold' recommendation is appropriate as the filing does not present new material information to change an existing investment stance.

Keywords

SEC filing, 10-K/A, Annual Report Amendment, Executive Compensation, Corporate Governance, Board of Directors, Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee, Related Party Transactions, Stock Options, Equity Compensation Plans, Sarbanes-Oxley Act, Dodd-Frank Act, Medical Device Company, Autonomix Medical